Redeye maintains its positive view of LIDDS after the Q1 report. The company continues to invest in its pipeline and advance its projects, in particular the promising nanodotax, and the formulation with a TLR9 agonist. The collaboration with Johnson&Johnson continues, which is a validation of the NanoZolid platform. We see significant potential in LIDDS' immunotherapy projects and think that the company has laid a strong foundation for the future.